Abstract
Background: Tamoxifen's cost-benefit ratio for breast ductal intraepithelial neoplasia (DIN) is unclear. Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed. Patients and methods: A total of 309 patients with DIN received low-dose tamoxifen as part of institutional guidelines and were compared with 371 patients with DIN who received no systemic treatment after surgery. Results: Women with estrogen receptor (ER)/progesterone receptor (PgR) >50% DIN who were not treated had a higher incidence of breast events than women on tamoxifen [hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.00-3.12] or women with ER/PgR 50% DIN, recurrence was higher in PgR ≥50% DIN than in PgR
Original language | English |
---|---|
Pages (from-to) | 949-954 |
Number of pages | 6 |
Journal | Annals of Oncology |
Volume | 21 |
Issue number | 5 |
DOIs | |
Publication status | Published - Oct 25 2009 |
Keywords
- Breast cancer
- DCIS
- Ductal intraepithelial neoplasia
- Low-dose tamoxifen
ASJC Scopus subject areas
- Oncology
- Hematology